文献速递肝病

核苷(酸)类似物停药后持续缓解率有限:全球多民族慢性乙型肝炎患者大型队列(RETRACT-B研究)结果

Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).
PubMed 文献 · Am J Gastroenterol · 2024-05-14

RETRACT-B研究纳入945例停药时HBsAg未消失且已停核苷(酸)类似物12个月的慢性乙型肝炎患者,分析停药12个月后的结局。停药48个月时持续缓解累积概率29.7%,病毒学复发65.2%,ALT flare 15.6%,HBsAg消失9.9%,再治疗34.9%。

要点

  • 停药48个月时持续缓解累积概率仅29.7%,病毒学复发达65.2%。
  • 停药后12个月内单次病毒学复发或ALT flare与后续持续缓解率显著降低相关。
  • 停药时HBsAg水平低、首年无严重或反复病毒学及生化复发者最适合停药。

核心结论

  • 尽管允许停药后12个月内HBV DNA和ALT波动,多数未获HBsAg消失的患者此后未维持持续应答。
  • 停药时HBsAg水平低、停药首年无严重或反复病毒学及生化复发者是最佳停药候选人群。

研究设计与样本

  • 纳入945例停药时HBeAg阴性、核苷(酸)类似物治疗下病毒抑制良好、停药12个月时HBsAg未消失且仍未治疗的患者。
  • 允许停药后12个月内HBV DNA和ALT波动,采用Kaplan-Meier法分析停药12个月后的结局。
  • 持续缓解定义为HBV DNA<2000 IU/mL且ALT<2倍正常值上限(ULN),ALT flare定义为ALT≥5倍ULN。

主要发现

  • 停药48个月时持续缓解累积概率29.7%,病毒学复发65.2%,平均峰值HBV DNA 5.0±1.5 log10 IU/mL。
  • 停药48个月时ALT flare累积概率15.6%,峰值ALT中位数8.3倍ULN(5.7-11.3)。
  • 停药48个月时HBsAg消失9.9%,再治疗34.9%。
  • 停药后12个月内单次病毒学复发或ALT flare与12个月后持续缓解率显著降低相关。

关键数值与推荐

  • 持续缓解:HBV DNA<2000 IU/mL且ALT<2倍ULN。
  • ALT flare:ALT≥5倍ULN。
  • 停药48个月时持续缓解累积概率29.7%,病毒学复发65.2%,ALT flare 15.6%,HBsAg消失9.9%,再治疗34.9%。
  • 停药12个月内单次病毒学复发或ALT flare与后续持续缓解率显著降低相关。

临床怎么用

  • 停药时HBsAg水平低的患者是核苷(酸)类似物停药的最佳候选人群。
  • 停药首年无严重或反复病毒学及生化复发者更适合停药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Complete viral suppression with nucleos(t)ide analogs (NAs) has led to a profound reduction in hepatocellular carcinoma and mortality among patients with chronic hepatitis B. Finite therapy yields higher rates of functional cure; however, initial hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) elevations are almost certain after treatment interruption. We aimed to analyze off-treatment outcomes beyond 12 months after NA cessation. METHODS: Patients with well-suppressed chronic hepatitis B who were hepatitis B e antigen-negative at NA cessation and remained off treatment without hepatitis B surface antigen (HBsAg) loss at 12 months were included (n = 945). HBV DNA and ALT fluctuations were allowed within the first 12 months. We used Kaplan-Meier methods to analyze outcomes beyond 12 months. Sustained remission was defined as HBV DNA <2,000 IU/mL and ALT <2× upper limit of normal (ULN) and an ALT flare as ALT ≥5× ULN. RESULTS: Cumulative probability of sustained remission was 29.7%, virological relapse was 65.2% with a mean peak HBV DNA of 5.0 ± 1.5 log 10 IU/mL, an ALT flare was 15.6% with a median peak ALT × ULN of 8.3 (5.7-11.3), HBsAg loss was 9.9% and retreatment was 34.9% at 48 months after NA cessation. A single occurrence of virological relapse or an ALT flare within the first 12 months off-treatment were associated with significantly lower rates of sustained remission beyond 12 months. DISCUSSION: Despite allowing for HBV DNA and ALT fluctuations within the first 12 months off-treatment, most patients without HBsAg loss did not maintain a sustained response thereafter. The best candidates for NA withdrawal are patients with low HBsAg levels at NA cessation, and those without profound or recurrent virological and biochemical relapses in the first off-treatment year.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Hirode G, Hansen BE, Chen CH, et al. Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study). Am J Gastroenterol. 2024. PMID: 38483300. doi:10.14309/ajg.0000000000002759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。